Live Breaking News & Updates on Entrectinib Rozlytrek

Stay updated with breaking news from Entrectinib rozlytrek. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Expands Entrectinib Indication in Pediatric Patients With NTRK+ Solid Tumors

The FDA has granted accelerated approval to entrectinib (Rozlytrek) for pediatric patients aged older than 1 month with solid tumors that harbor a NTRK gene fusion without a known acquired resistance mutation, are metastatic, or where surgical resection is likely to result in severe morbidity, and have progressed after treatment or have no satisfactory standard therapy options. ....

Entrectinib Rozlytrek , Ntrk Gene Fusion , Pediatric Cancer ,